We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00051181
Recruitment Status : Completed
First Posted : January 7, 2003
Last Update Posted : August 5, 2008
Sponsor:
Information provided by:

Study Description
Brief Summary:
To demonstrate that the intraocular pressure(IOP)-lowering efficacy of Travoprost (0.004%) is equal or better than that of Latanoprost 0.005% in patients with chronic angle-closure glaucoma.

Condition or disease Intervention/treatment Phase
Glaucoma, Angle-Closure Ocular Hypertension Drug: Travoprost (0.004%) Drug: Latanoprost (0.005%) Phase 3

Study Design

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma.
Study Start Date : January 2000
Primary Completion Date : June 2003
Study Completion Date : June 2003

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma
U.S. FDA Resources

Arms and Interventions


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Adult patients of any race and either sex with chronic angle-closure glaucoma.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00051181


Locations
United States, Texas
Asia
Fort Worth, Texas, United States
Australia
Australia
Sidney, Australia
Sponsors and Collaborators
Alcon Research
More Information

ClinicalTrials.gov Identifier: NCT00051181     History of Changes
Other Study ID Numbers: C-01-38
First Posted: January 7, 2003    Key Record Dates
Last Update Posted: August 5, 2008
Last Verified: August 2008

Keywords provided by Alcon Research:
Glaucoma
POAG
OAG
OHT

Additional relevant MeSH terms:
Glaucoma
Ocular Hypertension
Glaucoma, Angle-Closure
Eye Diseases
Latanoprost
Travoprost
Antihypertensive Agents